tbuckley/cabot-search huggingface dataset:
Differences in Patient Screening Mammography Rates Associated With Internist Gender and Level of Training and Change Following the 2009 U.S. Preventive Services Task Force Guidelines
Authors: Dawn J. Brooks
Journal: Journal of the National Comprehensive Cancer Network (2016)

Background: Significant discordance arose between screening mammography clinical practice guidelines published by different national health care organizations following the release of the U.S. Preventive Services Task Force (USPSTF) guidelines in 2009. This allowed for greater interprovider variation in clinical practice while remaining within standard of care. The objective of this study was to determine how differences in patient screening mammography rates between internal medicine physician subgroups defined by gender and level of training changed, if at all, following the release of the new guidelines. Methods: The study was an observational study including all internists and internal medicine residents at a single academic medical center, Dartmouth-Hitchcock Medical Center. Screening mammography rates were determined for patients of subgroups of internists defined by gender and level of training (attending vs resident physician) for the 2 years before and after the release of the updated screening guidelines. Results: Patients having female attending internists as their primary care provider were more likely to undergo screening mammography than those having male attending or resident internists of either gender both before and after the release of the new guidelines, with the difference in patient screening mammography rates between physician subgroups increasing following their release (rates before and after, respectively, by subgroup: female attending = 67%, 64%; male attending = 56%, 50%; female resident = 58%, 41%; male resident = 55%, 41%; P<.05). Conclusions: Internist gender and level of training are associated with differences in patient screening mammography rates at one academic medical center, with these differences increasing following the 2009 USPSTF guidelines. These findings suggest that the correlation between provider gender/level of training and a woman's likelihood of undergoing a screening mammogram strengthened as discordance arose between clinical guidelines published by different medical and health care advocacy groups. It is important for providers and patients both to be aware of correlations that exist between provider characteristics and patient cancer screening rates and to take steps to minimize the impact of provider bias on the shared decision-making process.
DNA repair and the risk of secondary leukemias.
Authors: S L Gerson
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.681 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636789 DNA repair and the risk of secondary leukemias. S L GersonxS L GersonSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.681 PDF "DNA repair and the risk of secondary leukemias.." Journal of Clinical Oncology, 14(2), pp. 681–682© 1996 by American Society of Clinical Oncology
THU0142 Prediction of Non-Adherence in Patients with Rheumatoid Arthritis
Authors: D. Choquette, L. Coupal, V. Nadon
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid arthritis (RA) is a very prevalent autoimmune disease. Adherence to prescribed drug is important to prevent irreversible joint damage. Unfortunately, adherence in this population is low, estimated to 60-70%. As a result, an approach by screening non-adherence potential behavior in patients would be valuable. Although a number of self-report medication adherence questionnaires exist, only the "Compliance Questionnaire on Rheumatology" (CQR) has been validated in english in patients with inflammatory arthropathies. The aim of this study is to evaluate the validity of a french version of the CQR and assess its possible use as a adherence screening tool. <h3>Objectives</h3> Establish the validity of the translated questionnaire in french and evaluate the possible predicting role of the CQR (Compliance questionnaire on rheumatology) for patients suffering from Rheumatoid Arthritis. Explore the validity of a short version of the CQR. <h3>Methods</h3> We conducted a longitudinal descriptive study. The inclusion criteria were: RA diagnosis, age over 18 years, RA duration≥1 year, and RA treatment for at least the previous six months (DMARD and/or biologic agent). Adherence was measured in two different methods: 1) patients completed the French version of the CQR questionnaire during a medical visit at the Institut de Rhumatologie de Montréal between November 11th and December 17th, 2013 and 2) the pharmaceutical profile for the six months preceding to the medical visit was obtained by contacting the individual pharmacist. The medical possession ratio (MPR) was then calculated for each patient, and compared to the result of the CQR questionnaire. <h3>Results</h3> 160 patients with rheumatoid arthritis were included in this study. All of them gave written informed consent. The preliminary results show an adherence rate to DMARD of 79.1%, which is slightly higher than the literature. The rate of adherence to hydroxychloroquine (HCQ) and methotrexate (MTX) are similar (80.6% vs 80.0%). The participants seem to be more adherent to oral medication compared to subcutaneous (83.8% vs 71.9%). Adherence calculated by the medical possession ratio (MPR) show that non-adherent patients correlate with a poorer result to their CQR questionnaire. The short version gave similar results compared to the original CQR. <h3>Conclusions</h3> The French version of the CQR questionnaire could become a useful tool to evaluate adherence in rheumatoid arthritis population. Further analysis and results are pending. <h3>Disclosure of Interest</h3> None declared
Factors in Improvement of Results in Varicose Vein Surgery
Authors: J C LUKE, J R GUTELIUS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0247 Flexor Tuberculous Tenosynovitis of the Hand: About 8 Cases
Authors: S. Miladi, D. Kaffel, R. Dhahri, I. Cherif, W. Hamdi, I. Zouch, M.M. Kchir
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Tuberculous infection of the musculoskeletal system count 10% of all extrapulmonary cases of tuberculosis (TB). In musculoskeletal tuberculous infections, the involvement of TB in peripheral joints and tendons is rare. In this report we will describe 8 cases of flexor tuberculous tenosynovitis (FTT). <h3>Objectives</h3> The aim of our work is to analyze the diagnostical, therapeutical and evolutionary aspects of this disease through a series of 8 cases of FTT patients treated. <h3>Methods</h3> A retrospective study was conducted selecting patients followed-up for FTT. Patients hospitalized during the period from 2008 till December 2014 were recruited. Previous history of TB or exposure to TB was searched. All patients underwent hands plain radiographies and ultrasounds, chests radiographies, tuberculin skin test (TST), sputum smears and cultures; then to surgical synovectomy with histological and bacterial examination. <h3>Results</h3> Eight patients were included (5 females, 3 males), with a mean age of 45 years-old [33 – 59]. All patients were immunocompetent and without a past medical history of TB. A local steroid injection preceding the infectious episode was noted in one case and a cow bite was revealed in another case. The mean period before consulting was 15 months [3-23]. Fever, night sweats and weight loss was noted in 3 patients. First symptom of illness was swelling of the palmar side in 4 cases, of the left 4th finger in 2 cases, of the right 5th finger in one case and a carpal tunnel syndrome in an another case. Hands plain radiographies weren9t contributive for the diagnosis, however ultrasound showed flexor tenosynovitis in all cases. Chest radiography revealed squeal of tuberculosis in one patient. TST was always positive but sputum smears and cultures were negatives in all cases. Histological examinations and bacterial culture confirm the diagnosis of FTT in all patients. Combination of anti-tuberculosis antibiotics was well conducted and evolution was good for all patients. <h3>Conclusions</h3> Although rarely seen, FTT should be kept in mind if we found chronic flexor tenosynovitis; a detailed medical history and careful clinical examination should be taken to prevent misdiagnosis. Histological examinations and bacterial culture are very important to confirm the diagnosis. <h3>Disclosure of Interest</h3> None declared
A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).
Authors: Jun Guo, Xi Nan Sheng, Zhihong Chi, Chuanliang Cui, Lu Si, Si Ming Li, Li Li Mao, BIN LIAN, Bixia Tang, Xieqiao Yan, Xuan Wang, Fang-Jian Zhou, Dingwei Ye, Zhisong He
Journal: Journal of Clinical Oncology (2015)

e15591 Background: There is no standard treatment in patients with renal cell carcinoma that was previously treated with VEGF-targeted therapies and mTOR inhibitors. From the Gold study, Sorafenib might be an option for the third-line treatment. This study aimed to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cancer. Methods: This study is an open-label, multi-center, randomized phase II trial. Eligible patients had metastatic renal cell carcinoma with clear cell, and had received 1st line treatment of sunitinib and 2nd line treatment of everolimus before enrollment. Additional inclusion criteria included: ≥ 1 measurable disease, ECOG PS 0/1, and adequate hematological, renal, and hepatic functions. Patients were randomly allocated in a 1:1 ratio to receive bevacizumab plus sorafenib (bevacizumab 5mg/kg intravenously every two weeks plus sorafenib 400 mg twice daily) or sorafenib alone (sorafenib 400 mg, orally, twice daily). Treatment was continued for both groups until occurrence of disease progression, unacceptable toxicity, death, or withdrawal of consent. The primary study endpoint is PFS. Overall survival, disease control rate, and safety will also be assessed. Results: The first patient visit was on October 1, 2013. Thirty-three of a planned 106 evaluable pts have been enrolled: 76% male, median age 63, 100% PS 0/1 and 33% favorable/55% intermediate by Heng’s criteria. 18 patients had received bevacizumab plus sorafenib, and 15 patients had received sorafenib alone. The objective response rate was 11.1% and 0% respectively. The median progression-free survival was 6.5 months and 3.5 months respectively. The median overall survival has not been reached. Treatment emergent grade 3 or 4 adverse events were fatigue (11.1%), hypertension (5.6%), proteinuria(5.6%) in bevacizumab group; palmar-plantar erythrodysaesthesia (6.7%) in sorafenib alone group Conclusions: Bevacizumab plus sorafenib might be beneficial for the advanced renal cancer patients who have failed to sunitinib as 1st and everolimus as 2nd line treatment. Clinical trial information: NCT02330783.
AB0780 Correlation Between Disease Duration and Long Term Loss of Work Disability in Patients with Ankylosing Spondylitis
Authors: M. Podryadnova, R.M. Balabanova, T.V. Dubinina, M.M. Urumova, S.F. Erdes
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Long term loss of work capacity is one of socially significant sequelae of any chronic condition, including ankylosing spondylitis (AS). <h3>Objectives</h3> To analyze causes and predictors of long term loss of work disability in AS patients. <h3>Methods</h3> The study included 220 consecutive AS patients (162 males and 58 females), fulfilling criteria 1984 y., hospitalized during the period 2012-13 yy. Mean patients9 age was 35,1±9,5 y, mean age at disease onset - 30,0±9,7 y. 92% of patients were HLA-B27-positive, disease activity by BASDAI - 4,6±2,1, ASDAS<sub>CRP</sub> - 3,3±1,3. Functional impairment BASFI index was 4,1±2,6. <h3>Results</h3> 56,4% patients out of 220 presented with long term loss of work disability. Mean age of patients with long term loss of work disability was 36,7±9,7 y. ROC-curve analysis indicated BASFI as most significant prognostic factor of long term loss of work disability. Threshold BASFI value of 4,7 allows to predict in an individual patient long term loss of work disability with (52,8%) sensitivity and (76,3%) specificity. AS duration was not a predictor of long term loss of work disability, although with longer AS duration the rate of long term loss of work disability was also increasing, i.e. from 32% by the end of the 2nd year to 63% - by the end of the 4th year. <h3>Conclusions</h3> Functional impairment with BASFI threshold of 4,7 allows to predict a long term loss of work disability in a particular patient with high sensitivity and specificity. <h3>Disclosure of Interest</h3> None declared
PTU-235 Assessment of patient’s health related quality of life (HRQL) following elective laparoscopic colorectal surgery for complicated diverticulitis
Authors: IH Mallick, S Mbarushimana, KK Sasapu
Journal: Gut (2015)

<h3>Introduction</h3> Complicated Diverticulitis leads to lower quality of life. Health related quality of Life (HRQL) outcomes are arguably the most important elements of success of treatment. The aim of our study was to measure quality of life using validated health status instruments, of patients who have undergone elective laparoscopic colorectal resection for complicated diverticulitis such as fistula, recurrent diverticulitis leading to stricture. <h3>Method</h3> Medical notes of all patients with complicated diverticulitis who underwent elective Laparoscopic colectomy in our hospital between 2012 and 2014 were reviewed. SF-36 and EuroQuol survey are validated instruments for measuring HRQL. <h3>Results</h3> 24 patients underwent laparoscopic sigmoid colectomy for complicated diverticular disease (stricture = 12; fistulas = 12). 17 were males and 7 females. Age group ranged from 41 to 78 (median 56.5). Primary anastomosis (n = 20), Hartmann’s procedure (n = 1) and primary anastomosis with defunctioning loop ileostomy (n = 3). Post operatively, no complications (n = 16), anastomotic leaks (n = 2), ileus (n = 4), new onset atrial fibrillation (n = 1) and pneumonia (n = 1). The two patients with anastomotic leaks were taken back to operating theatre for laparoscopic washout and drain insertion. No patients had conversions. Telephone survey using SF36 and EuroQol questionnaires was undertaken at a median follow-up of 7 months. Twenty patients responded. Median SF36 scores were physical function 84, physical role 86.5, body pain 78.5, general health 67, vitality 57, social function 77, emotional role 80.5, mental health 74.5. Median EuroQol score was 0.80. All the SF36 scores were within the normal range, as were the EuroQol scores. <h3>Conclusion</h3> The health related quality of life for patients who have undergone laparoscopic colectomy for complicated diverticulitis measured using validated health status instruments were normal. <h3>Disclosure of interest</h3> None Declared.
A Unified Probabilistic Framework for Dose–Response Assessment of Human Health Effects
Authors: Weihsueh A. Chiu, Wout Slob
Journal: Environmental Health Perspectives (2015)

When chemical health hazards have been identified, probabilistic dose-response assessment ("hazard characterization") quantifies uncertainty and/or variability in toxicity as a function of human exposure. Existing probabilistic approaches differ for different types of endpoints or modes-of-action, lacking a unifying framework.
THU0128 Characteristics of Patients with Rheumatoid Arthritis in Kuwait: Results from the Krrd Registry
Authors: A.A. Al-Herz, K. Saleh, A. Al-Awadhi, W. Al-Kandari, E. Hasan, F. Abutiban, A. Alenizi, A. Ghanem, M. Hussain, Y. Ali, A. Khadrawy, A. Fazal, K. Mokaddem, B. Aftab, N. Haider, A. Zaman, G. Mazloum, Y. Bartella, A. Al-Saber, J.M. Esdaile
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To describe characteristics of patients with RA in Kuwait focusing on demographic and serological features and common comorbidities and compare them with other RA populations. <h3>Methods</h3> Adult patients with RA enrolled in The Kuwait Registry for Rheumatic Diseases (KRRD) from February 2013 through May 2014 were studied. They were recruited from the rheumatology departments of four major hospitals in Kuwait. Demographic, clinical and laboratory data were collected via rheumatologists and trained nurses through patient interviews and from medical records. A comparison with Kuwaiti general population and other RA populations were made. Statistical tests were applied where appropriate. <h3>Results</h3> 556 patients were enrolled with a mean age of 49+12 years (range, 17-74) and disease duration of 3.1+5 years. RA diagnosis was made at an age of 46+13 years (14-71). 76.8% were female. 12.9% had a family history of an inflammatory autoimmune rheumatic disease. Only 3.6% had rheumatoid nodules. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (ACA) were detected in 73% and 58%, respectively. Both were positive in 47.7% (r=0.287, p=0.001). Both ACA and a combination of RF and ACA were more prevalent in females (p=0.034, 0.001, respectively). About one third of male patients were smokers versus 3.4% of females with no significant correlation between smoking and RF or ACA. Anti-nuclear antibody test was positive in 12%. Diabetes mellitus (DM) and hypertension were the commonest co- morbidities, being detected in a total of 36.2%, hyperlipidemia in 7.4% and coronary artery disease (CAD) in 2.7%. Only 3 cases of cancer were reported, all of them were solid cancers. <h3>Conclusions</h3> RA in Kuwait manifests at a younger age and with a higher prevalence of positive family history than in other RA populations. CAD was less frequent which may be related to lower rates of hypertension, hyperlipidemia and smoking in our registry. A higher prevalence of DM, however, reflects a high background prevalence of DM in Kuwait. <h3>Disclosure of Interest</h3> None declared
Gemcitabine-oxaliplatin combination (GEM-OHP) in metastatic non-small cell lung cancer (NSCLC): Final results of a phase II study
Authors: P. Lippe, P. Mazzanti, F. Recchia, C. Massacesi, C. Cappelletti, L. Imperatori, G. Laici, M. Bonsignori, R. Mattioli
Journal: Journal of Clinical Oncology (2005)

7293 Background: Platinum-based regimens are a standard in inoperable NSCLC. Due to its carrier ligand DACH, OHP has potential advantages in terms of activity and toxicity compared to cisplatin and carboplatin and has shown activity in NSCLC. GEM-OHP combination has been tested in a number of phase I-II studies. On the basis of these observations a phase II study of GEM-OHP combination was initiated in metastatic NSCLC patients (PTS). Methods: The study protocol was approved by ethics committees of the participating centres and all enrolled PTS gave written informed consent. According to Simons’s to-two step optimal design, to be considered interesting, GEM-OHP had to produce at least 5 objective responses in the first 19 PTS. Treatment was GEM 1250 mg/m2 d 1, 8 and OHP 120 mg/m2 d 8, every 3 weeks. Disease parameters were evaluated at study entry and after 3 cycles of GEM-OHP. Results: Nineteen chemo-naive stage IV NSCLC PTS were enrolled and 18 of them are evaluable for response (1 early death due to stroke after the first cycle). Median age was 60 years (r. 44–75), male/female ratio 18/1, ECOG PS 0 in 8, 1 in 6 and 2 in 5 PTS. Three objective responses (1 CR and 2 PR) were recorded (RR = 15.8%); the CR was observed in a PT with single lymph-node metastasis. 14 PTS had PD (73.6%) and 1 SD (5.3%). Toxicity was mild, with neutropenia, thrombocytopenia, acute neurotoxicity, vomit and transaminases elevation as the principal adverse events, but with one severe life-threatening allergic shock from OHP. No treatment-related death was recorded. The study was closed with 18 evaluable PTS due to the mathematical impossibility of reaching 5 responses with the enrolment of one more PT. Conclusions: This combination of GEM and OHP failed to show activity in metastatic NSCLC and is not recommended in clinical practice or in future trials. No significant financial relationships to disclose.
Comment on “ <i>In Vitro</i> Effects of Bisphenol A β-D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytes”
Authors: Véronique Gayrard, Glenn Gauderat, Marlène Z. Lacroix, Catherine Viguié, Alain Bousquet-Melou, Pierre-Louis Toutain, Nicole Picard-Hagen
Journal: Environmental Health Perspectives (2015)
Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation
Authors: J C Garbutt, J P Mayo, G M Gillette, K Y Little, G A Mason
Journal: American Journal of Psychiatry (1986)

Four patients whose depressions were failing to respond to administration of tricyclic antidepressants were given separate trials of T3 and lithium. In all four cases, T3 failed to potentiate the antidepressant, whereas the lithium did.
Ebola Virus Disease in Health Care Workers — Guinea, 2014
Authors: Margaret Grinnell, Meredith G. Dixon, Monica Patton, David Fitter, Pépé Bilivogui, Candice Johnson, Ellen Dotson, Boubacar Diallo, Guenael Rodier, Pratima Raghunathan
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

An outbreak of Ebola virus disease (Ebola) began in Guinea in December 2013 and has continued through September 2015. Health care workers (HCWs) in West Africa are at high risk for Ebola infection owing to lack of appropriate triage procedures, insufficient equipment, and inadequate infection control practices. To characterize recent epidemiology of Ebola infections among HCWs in Guinea, national Viral Hemorrhagic Fever (VHF) surveillance data were analyzed for HCW cases reported during January 1–December 31, 2014. During 2014, a total of 162 (7.9%) of 2,210 laboratory-confirmed or probable Ebola cases among Guinean adults aged ≥15 years occurred among HCWs, resulting in an incidence of Ebola infection among HCWs 42.2 times higher than among non-HCWs. The disproportionate burden of Ebola infection among HCWs taxes an already stressed health infrastructure, underscoring the need for increased understanding of transmission among HCWs and improved infection prevention and control measures to prevent Ebola infection among HCWs.